AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06485167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFEM- chair
Description: The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
Study NCT06485167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HIFEM- chair
Description: The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
Study NCT05793684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Study NCT05675397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: donor human milk
Description: Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
Study NCT05675397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: donor human milk
Description: Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
Study NCT05280782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
Study NCT05950555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: We used 0.9% isotonic sodium chloride.
Study NCT05950555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
Study NCT05466682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)
Description: Relaxation technique delivered via RELAXaHEAD app.
Study NCT05466682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
Study NCT05950555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
Study NCT04039789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project active legs
Description: Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
Study NCT04039789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
Study NCT04039789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
Study NCT06790342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystine
Description: Used for smoking cessation and alcohol reduction
Study NCT06166888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK131
Description: AK131 is an anti-PD-1 and CD73 bispecific antibody
Study NCT02556970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port VATS
Description: Performing video-assisted thorascopic surgery through a single port
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1g intraoperatively
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g intraoperatively
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 75mg intraoperatively
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 75mg intraoperatively
Study NCT05990153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clinical practice drug treatment
Description: drug treatment according to the medical indications of clinical practice
Study NCT05990153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Description: The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
Study NCT02556970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Camera (5mm diameter 30 degree videothoracoscope)
Study NCT02556970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camera (5mm diameter 30 degree videothoracoscope)
Study NCT02556970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps grasper
Study NCT06790342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free
Description: An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
Study NCT02556970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forceps grasper
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Levobupivicaine intercostal nerve block
Description: Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
Study NCT05990153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE)
Description: The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
Study NCT05940753 — intervention group
Intervention type: OTHER
Intervention: Survey about travel willingness regarding cancer treatment and follow-up
Description: No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
Study NCT02556970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Levobupivicaine intercostal nerve block
Description: Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
Study NCT06348758 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: E-Questionnaire will be sent to the students
Study NCT04742036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
Study NCT04742036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression.
Study NCT04775394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
Study NCT05137275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-5T4 CAR-raNK Cells
Description: In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
Study NCT05051033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
Study NCT05051033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter edge-to-edge repair
Description: Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
Study NCT05581628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain location inventory (PLI)
Description: PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
Study NCT05581628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Symptom Impact Questionnaire (SIQR)
Description: The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
Study NCT05581628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Description: FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
Study NCT06350357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punching closure
Description: The hole clamping and the grooves hold the metal clips better
Study NCT06350357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional clipping
Description: Metal lip closure is one of the most commonly used closure methods
Study NCT06163729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy
Description: Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
Study NCT05686850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flow Oxygen
Description: Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
Study NCT05686850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen
Description: Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
Study NCT05686850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
Study NCT05846204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught.
Study NCT05846204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercise Group-DBE
Description: Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
Study NCT05999929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
Study NCT04531397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACEI treatment
Description: ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
Study NCT04531397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin+ACEI treatment
Description: Dapagliflozin will be given 10 mg/day (weight>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
Study NCT05132595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Study NCT05132595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine at high dose
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
Study NCT05132595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine at low dose
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
Study NCT05132595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac at high dose
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
Study NCT05132595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac at low dose
Description: After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
Study NCT05054231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
Study NCT06261476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha (Withnia somnifera)
Description: Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
Study NCT05668026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
Study NCT05668026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
Study NCT05369533 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
Study NCT05369533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
Study NCT05369533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet Pill
Description: Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
Study NCT05369533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
Study NCT04905030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information T1
Description: A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
Study NCT04905030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information T2
Description: A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
Study NCT04905030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information C
Description: A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
Study NCT06790342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched to cystine
Study NCT06790342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to cystine
Study NCT06790342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standardized brief advice to quit smoking (standard of care)
Study NCT06790342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standardized brief advice to quit smoking (standard of care)
Study NCT05338658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide Alarm Therapy (PAT)
Description: PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.